Immunome Inc. (IMNM)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Collaboration revenue | 4,015 | 2,926 | 2,910 | 2,364 |
| Research and development | 40,451 | 36,872 | 37,200 | 29,083 |
| General and administrative | 10,042 | 10,690 | 9,526 | 6,978 |
| In-process research and development | - | - | 6,706 | 6,312 |
| Total operating expenses | 50,493 | 47,562 | 53,432 | 42,373 |
| Loss from operations | -46,478 | -44,636 | -50,522 | -40,009 |
| Interest income | 3,081 | 2,996 | 3,422 | 3,887 |
| Net loss | -43,397 | -41,640 | -47,100 | -36,122 |
| Earnings per share, basic | -0.5 | -0.52 | -0.78 | -0.6 |
| Earnings per share, diluted | -0.5 | -0.52 | -0.78 | -0.6 |
| Weighted average number of shares outstanding, basic | 87,010,742 | 79,410,354 | 60,205,327 | 59,936,703 |
| Weighted average number of shares outstanding, diluted | 87,010,742 | 79,410,354 | 60,205,327 | 59,936,703 |